Fiona Simpkins
NRG Oncology · University of Pennsylvania · Abramson Cancer Center at Penn Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fiona Simpkins as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:47 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05950464 · Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerNational Cancer Institute (NCI) · recruiting · Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma · principal investigator
- Ph2NCT03462342 · Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerUniversity of Pennsylvania · completed · High Grade Serous Carcinoma · principal investigator
- Ph1NCT02637934 · Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CTAbramson Cancer Center at Penn Medicine · active not recruiting · Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · principal investigator
- Ph1NCT02363829 · A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)Abramson Cancer Center at Penn Medicine · completed · Uterine Cervix Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Developing biomarkers of response for a new therapy in ovarian cancerR01CA285965 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2024 to 2026 · $676,415 awarded in 2026Same name and institution; not confirmed by an ID
- Platform to develop targeted therapies for aggressive less common gynecological cancersU54CA283759 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2023 to 2026 · $256,669 awarded in 2026Same name and institution; not confirmed by an ID
- A novel more effective genotoxic therapy for ovarian cancerR37CA215436 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2018 to 2024 · $378,217 awarded in 2024Same name and institution; not confirmed by an ID
- Targeting SRC Signaling Pathways to Promote Cell Cycle Arrest in Ovarian CancerK08CA151892 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2011 to 2016 · $130,770 awarded in 2016Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT05950464
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:47 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial.Obstet Gynecol · 2009129 citationsRCR 3.9
- Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.Gynecol Oncol · 2021118 citationsRCR 5.9
- A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.J Clin Invest · 2018117 citationsRCR 3.7
- A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).Gynecol Oncol · 201548 citationsRCR 1.5
- Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study.Cancer Immunol Res · 201345 citationsRCR 1.2
- 35 citationsRCR 2.8
- Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.Gynecol Oncol · 202228 citationsRCR 1.7
- Studies of working memory using 18FDG-positron emission tomography in normal controls and subjects with epilepsy.Life Sci · 199615 citationsRCR 0.5
- 11 citationsRCR 0.7
- 9 citationsRCR 2.0